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Abstract
Background: Sodium bicarbonate (NaHCO3) is a well-established nutritional ergogenic aid, though gastrointestinal
(GI) distress is a common side-effect. Delayed-release NaHCO3 may alleviate GI symptoms and enhance bicarbonate
bioavailability following oral ingestion, although this has yet to be confirmed.
Methods: In a randomised crossover design, pharmacokinetic responses and acid-base status were compared
following two forms of NaHCO3, as were GI symptoms. Twelve trained healthy males (mean ± SD age 25.8 ± 4.5 years,
maximal oxygen uptake ( _VO2 max) 58.9 ± 10.9 mL kg min
−1, height 1.8 ± 0.1 m, body mass 82.3 ± 11.1 kg, fat-free mass
72.3 ± 10.0 kg) underwent a control (CON) condition and two experimental conditions: 300mg kg−1 body mass
NaHCO3 ingested as an aqueous solution (SOL) and encased in delayed-release capsules (CAP). Blood bicarbonate
concentration, pH and base excess (BE) were measured in all conditions over 180min, as were subjective GI symptom
scores.
Results: Incidences of GI symptoms and overall severity were significantly lower (mean difference = 45.1%, P < 0.0005
and 47.5%, P < 0.0005 for incidences and severity, respectively) with the CAP than with the SOL. Symptoms displayed
increases at 40 to 80 min post-ingestion with the SOL that were negated with CAP (P < 0.05). Time to reach
peak bicarbonate concentration, pH and BE were significantly longer with CAP than with the SOL.
Conclusions: In summary, CAP can mitigate GI symptoms induced with SOL and should be ingested earlier
to induce similar acid-base changes. Furthermore, CAP may be more ergogenic in those who experience
severe GI distress with SOL, although this warrants further investigation.
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Key Points
 Delayed-release NaHCO3 mitigated GI distress
compared with the aqueous solution ingestion form;
therefore, athletes who have experienced problematic
side-effects in the past may now benefit from
supplementation.
 Time to reach peak blood bicarbonate increased
with delayed-release NaHCO3, and therefore,
requires earlier ingestion (~ 48 min) in comparison
with the aqueous solution ingestion form.
 Bicarbonate bioavailability was enhanced in some
individuals with delayed-release NaHCO3; hence,
ingestion should be based upon individual
concentration-time profiles in conjunction with GI
symptoms.
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Background
Sodium bicarbonate (NaHCO3) is a well-established nu-
tritional ergogenic aid. Supplementation can improve
short-duration (~ 1–10min), high-intensity exercise per-
formance [1], with various meta-analyses confirming its
efficacy [2–4]. As an extracellular buffering agent,
NaHCO3 enhances endogenous bicarbonate buffering
capacity by inducing significant, albeit transient, eleva-
tions in extracellular bicarbonate. Consequently, this en-
hances efflux of hydrogen cations (H+) from skeletal
muscle, therefore delaying muscle fatigue and positively
affecting numerous performance variables, such as
power output [5] and time to exhaustion [6]. While it re-
mains unclear whether minimal increases are required
to achieve these benefits, substantial changes (~ 6
mmol∙L−1) in blood bicarbonate may improve the likeli-
hood of performance-enhancing effects [2, 7]. Given that
bicarbonate is lost in the neutralisation of gastric acid
[8], large oral doses (200–300 mg kg−1 body mass) are
required to induce meaningful elevations in the blood.
Acute gastrointestinal (GI) distress is a known
side-effect of ingesting large amounts of NaHCO3 [9],
particularly when administered as an aqueous solution
[10]. Ergogenic effects have still been observed in those
reporting GI distress [1, 11]; however, there is evidence
to suggest that GI distress may be ergolytic for some in-
dividuals [1, 12–14]. Furthermore, some authors have
suggested that GI distress may deter individuals from
using NaHCO3 regardless of its potential ergogenic ben-
efits [7]. Although the impact of GI distress on perform-
ance remains ambiguous, symptoms such as vomiting
and diarrhoea may present a major practical limitation
for athletes and coaches.
Polymeric-coated compounds can resist gastric degrad-
ation and reduce GI symptoms provoked by acid sensitive
compounds, such as NaHCO3 [15]. Hydroxypropyl methyl-
cellulose, contained in delayed-release capsules, can resist
degradation in acidic environments (pH ~ 1–2 arbitrary
units (AU)), and therefore, provides gastro-resistant proper-
ties. Instead, degradation occurs in the duodenum where
the pH is far more alkaline (pH ~ 6–7AU) and absorption
can take place rapidly. Since GI distress is partly attribut-
able to degradation in the stomach [8], it has been
suggested that gastro-resistant capsules may alleviate symp-
toms that are typical with NaHCO3 ingestion [16]. Given
that less bicarbonate is lost in the stomach, it has also been
suggested that smaller doses may produce comparable
acid-base changes to larger doses [16]. In contrast, as gut
transit time is reduced with gastro-resistant formula-
tions [15], this may reduce bicarbonate bioavailability
when administered in this form. No study to date has
examined the use of delayed-release NaHCO3 on
markers of GI distress, nor on bicarbonate bioavail-
ability and subsequent blood acid-base responses.
Reducing GI distress following NaHCO3 ingestion
may enhance use by athletes, particularly among
those who are deterred by potential side-effects.
Therefore, the aim of this study was to investigate
whether delayed-release NaHCO3 could mitigate GI dis-
tress compared with an aqueous solution, as well as to
compare the pharmacokinetic and acid-base responses.
It was hypothesised that delayed-release NaHCO3 would
reduce GI symptoms and display at least bioequivalence
when compared to an aqueous solution.
Methods
Participants
Twelve trained [17] healthy males (mean ± SD age 25.8
± 4.5 years, maximal oxygen uptake ( _VO2 max ) 58.9 ±
10.9 mL kg min−1, height 1.8 ± 0.1 m, body mass 82.3 ±
11.1 kg, fat-free mass 72.3 ± 10.0 kg) were recruited for
the study. The study was approved by the University Re-
search Ethics Committee (URESC) before the partici-
pants gave written informed consent to take part in the
study. Inclusion in the study required that participants
had performed regular (≥ 3 days week−1) physical exer-
cise for at least 2 years. Exclusion criteria included inges-
tion of any buffering agents < 6 months prior to
commencing the study and those with hypertension or
on a sodium-restricted diet.
Study Overview
Before taking part in the experimental trials, each par-
ticipant underwent a baseline assessment over two la-
boratory visits separated by at least 48 h to establish
(1) body composition and _VO2 max and (2) fluctuations
in blood analytes (HCO3
−, pH and base excess) under
normal conditions. Fluctuations in blood analytes and
GI symptoms under normal conditions were used as a
control (CON) measure throughout. In the experi-
mental trials, all participants underwent two condi-
tions: 300 mg kg−1 body mass NaHCO3 administered
as either an aqueous solution (SOL) or encased in
delayed-release capsules (CAP). Experimental trials
were administered in a block randomised crossover
design that was counterbalanced (Latin square) in
order of administration and took place at least 7 days
apart to allow for the washout of residual NaHCO3
[18]. Participants were required to abstain from alco-
hol or caffeine-containing beverages for 12 h and from
strenuous exercise 24 h before each laboratory visit.
All sessions took place under standardised laboratory
conditions (temperature = 21–22 °C, relative humidity
= 50–55%, barometric pressure = 756–759 mmHg) and
were conducted at 0900 h to account for circadian
rhythms [19].
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Baseline Assessment
Participants arrived at the laboratory on both occasions
after an overnight fast (~ 12 h) and euhydrated. On one
visit, semi-nude body mass and fat-free mass were
assessed using whole-body air displacement plethysmog-
raphy (BOD POD®, COSMED, Italy). Participants then
performed an incremental exercise test to volitional ex-
haustion on an electromagnetically braked cycle ergom-
eter (Excalibur Sport, Lode, Netherlands). After a
standardised 5-min warm-up at a power output of 70
watts (W), the cycling protocol commenced at 75W for
1 min and workload increased by 1W every 2 s (30
W min−1) until volitional exhaustion. This was deter-
mined by the inability of the participant to sustain their
respective self-selected cadence for > 5 s despite feedback
and strong verbal encouragement. On a separate visit,
fingertip capillary blood samples were obtained using an
aseptic technique after the participants were quietly
seated for 20 min. Blood samples were drawn every 20
min over 180 min, with 10min sampling between 80 and
140 min to accurately capture peak values [20]. Blood
samples were collected in 100-μL heparin-coated glass
clinitubes (Radiometer Medical Ltd., Denmark) and im-
mediately analysed using a blood gas analyser (ABL800
BASIC, Radiometer Medical Ltd., Denmark). At the
same time points, GI symptoms were recorded using a
9-item questionnaire, including nausea, flatulence, stom-
ach cramping, belching, stomach ache, bowel urgency,
diarrhoea, vomiting and stomach bloating [10]. Symp-
toms were self-measured on a 10-cm scale, the ends of
which were marked “0, no symptom” and “10, severe
symptom”, as previously described [11]. Participants
remained seated throughout, although toilet breaks were
permitted. No food was consumed during the experi-
mental trials, and water was permitted ad libitum, with
volumes replicated in the subsequent experimental
session.
Experimental Trials
Treatment condition SOL was prepared in 400 mL of
natural mineral water (Evian®, France) and mixed with
50mL of sugar-free blackcurrant flavoured squash
(Robinsons®, UK) and refrigerated (~ 1 h) to enhance pal-
atability [11]. For the CAP condition, size 00 capsules
(DRcaps™, Capsugel®, France) were prefilled with
NaHCO3 using a capsule filler (Capsule Connection
LLC, USA), while doses were checked for accuracy using
digital laboratory scales (Fisher, OHAUS™). Participants
were instructed to ingest either the SOL or CAP with an
equal volume (400mL) of water within 10 min while the
stopwatch commenced parallel with the start of inges-
tion [20, 21]. All experimental trials were conducted
under the same conditions as the CON trial, and blood
analytes and GI symptoms were measured as previously
described.
Statistical Analysis
Prospective statistical power analysis was conducted a
priori to determine that 12 participants were required,
with alpha and beta set at 0.05 and 0.20, respectively.
Data were assessed for normality using standard graph-
ical methods prior to analyses [22]. Two-way analysis of
variance (ANOVA) with repeated measures (condition ×
time) was used to establish significant main effects for
blood analytes (HCO3
−, pH and BE) and GI symptom
scores. Condition consisted of two levels (SOL and
CAP), whereas time consisted of 13 (0, 20, 40, 60, 80,
90, 100, 110, 120, 130,140, 160 and 180 min). Effect sizes
were calculated using partial eta squared (η2) for
ANOVA and were interpreted according to Cohen [23]
as follows: trivial < 0.20, small 0.20–0.49, moderate
0.50–0.79 and large ≥ 0.80. Blood analytes and GI symp-
tom scores were then analysed using one-way ANOVA
to establish differences at individual time points. Spher-
icity was assessed using Mauchly’s test throughout.
Where appropriate, corrections for violations of spher-
icity (Greenhouse-Geisser) and multiple comparisons of
differences within a factor (Bonferroni) were made [24].
Mean pharmacokinetic variables and highest GI
symptom score between conditions were analysed by
paired-sample t test. Descriptive data are presented as
mean ± SD unless stated otherwise. The α-level of stat-
istical significance was set at P < 0.05, and exact P
values are given in the text and tables. Values for P
of “0.000” given by the statistical package were cor-
rected to “< 0.0005” [25]. Data were analysed using
the Statistical Package for the Social Sciences (SPSS®)
for Windows® (IBM, Chicago, IL, USA), version 25.
Results
Gastrointestinal Distress
No GI symptoms were reported pre-ingestion, nor at
any time point in the CON condition. All participants
(N = 12) experienced at least one GI symptom following
SOL and CAP ingestion (Table 1). Stomach bloating was
the most prevalent GI symptom in both experimental
trials, although this was lower with CAP (58%) than with
SOL (100%). Overall, fewer GI symptoms (mean differ-
ence = 45.1%) were reported with CAP than with SOL
(Fig. 1a). Incidences of GI distress peaked at 40 min
post-ingestion under both conditions (Fig. 1a), which
was predominantly due to belching and bowel urgency.
Overall GI symptoms increased in the SOL (P < 0.0005)
and CAP (P < 0.017) conditions beyond those observed in
the CON condition. There was a significant effect of in-
gestion form (F1.00, 11.00 = 21.13, P = 0.001, η
2 = 0.66), with
less severe GI symptoms reported with CAP than with the
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SOL (P = 0.001) (Fig. 1b). There was no effect of time (F2.85,
31.36 = 2.89, P = 0.053, η
2 = 0.21), although symptoms at 40
min were significantly greater than pre-ingestion (P = 0.03).
No significant interaction was found (F3.22, 35.39 = 1.87, P =
0.148, η2 = 0.15). Overall GI symptoms were significantly
greater with the SOL at 20 (P = 0.004), 40 (P < 0.0005), 60
(P = 0.002), 80 (P = 0.001), 90 (P = 0.002) and 120 (P =
0.018)min post-ingestion than in the CON condition.
Symptoms were significantly lower at 40 (P = 0.004), 60 (P
= 0.035) and 80 (P = 0.017)min post-ingestion with CAP
than with the SOL. Gastric symptoms were significantly
lower at 40 (P = 0.006), 60 (P = 0.020) and 80 (P = 0.021)
min post-ingestion with CAP than with the SOL, while no
significant differences were reported for intestinal symp-
toms (P > 0.05). There was a significant difference in the
most severe GI symptom experienced in the SOL (7.21 ±
2.48 AU) and CAP (4.29 ± 2.12 AU) conditions (P = 0.002),
respectively (Table 1). Time to reach the most severe indi-
vidual GI symptom was greater with the SOL (87.50 ±
50.29min) than with CAP (75.00 ± 32.33min), although
these were not significant (P > 0.05).
Bicarbonate Bioavailability
Ingestion form had no significant effect on bicarbonate
concentration (F1.00, 11.00 = 0.71, P > 0.05, η
2 = 0.061) up
to 180 min post-ingestion. There was a significant effect
of time (F2.38, 26.23 = 101.74, P < 0.0005, η
2 = 0.90); bicar-
bonate concentration increased notably for 60 min fol-
lowing ingestion of the SOL, until a decrease occurred
from the previous time point at 180 min (P = 0.004)
post-ingestion (Fig. 2). In the CAP condition, bicarbon-
ate concentration rose progressively between 40 and 90
min, after which bicarbonate did not significantly change
(P > 0.05). A significant interaction was found between
Table 1 The most severe individual GI symptom reported
during any trial. Symptom scores are displayed in parenthesis
and are expressed as arbitrary units (AU)
Participant CON SOL CAP
1 Nil (0.0) Stomach cramp (3.5) Stomach bloating (3.0)
2 Nil (0.0) Bowel urgency (7.0) Stomach bloating (3.0)
3 Nil (0.0) Nausea (6.0) Nausea (2.0)
4 Nil (0.0) Diarrhoea (10.0) Stomach bloating (7.0)
5 Nil (0.0) Diarrhoea (10.0) Diarrhoea (7.0)
6 Nil (0.0) Diarrhoea (10.0) Diarrhoea (5.5)
7 Nil (0.0) Bowel urgency (6.0) Bowel urgency (5.0)
8 Nil (0.0) Bowel urgency (10.0) Bowel urgency (2.0)
9 Nil (0.0) Diarrhoea (10.0) Belching (3.0)
10 Nil (0.0) Diarrhoea (10.0) Belching (3.0)
11 Nil (0.0) Stomach ache (3.0) Belching (3.0)
12 Nil (0.0) Diarrhoea (10.0) Diarrhoea (7.0)
Mean (SD) 0.00 ± 0.00 7.96 ± 2.73 AU 4.21 ± 1.97 AU
Fig. 1 Incidence (a) and mean (±SD) severity (b) of GI symptoms.
The asterisk denotes significant difference between SOL and CAP
conditions (P < 0.05)
Fig. 2 Mean (± SD) blood bicarbonate concentrations. The
asterisk denotes significant difference between SOL and CAP
conditions (P < 0.05)
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condition and time (F2.31, 25.44 = 16.48, P < 0.0005, η
2
= 0.60). Bicarbonate concentrations were significantly
higher with the SOL at 20 (P = 0.008), 40 (P = 0.001)
and 60 (P = 0.011) min post-ingestion than with the
CAP and significantly lower at 130 (P = 0.021), 140
(P = 0.019) and 160 (P = 0.047) min post-ingestion.
Mean pharmacokinetic variables were similar between
conditions (Table 2). There was a delay in the absorption
of bicarbonate with CAP; lag time (Tlag) was greater with
CAP than with SOL (P = 0.002), as was the time to reach
peak bicarbonate concentration (P < 0.0005). Peak bicar-
bonate concentration (Cmax), change in bicarbonate con-
centration (ΔCmax) and area under the curve (AUC0-3h)
increased in the SOL and CAP conditions (P < 0.005)
compared with the CON, with no significant differences
between conditions (P > 0.05). However, a greater number
of participants reached a 5mmol L−1 (SOL N = 10, CAP
N = 11) and 6mmol L−1 (SOL N = 8, CAP N = 9) increase
in bicarbonate with CAP than with the SOL (Fig. 3).
Acid-Base Balance
Ingestion form had no significant effect on pH (F1.00,
11.00 = 2.88, P > 0.05, η
2 = 0.21) up to 180 min
post-ingestion. There was a significant effect of time
(F4.42, 48.60 = 43.74, P < 0.0005, η
2 = 0.80); pH increased
markedly for 60 min following ingestion of the SOL,
until a decrease occurred from the previous time point
at 180 min (P = 0.004) post-ingestion (Fig. 4). In the CAP
condition, pH rose progressively between 40 and 90min,
after which pH did not significantly change (P > 0.05). A
significant interaction was found between condition and
time for pH (F4.88, 53.67 = 6.42, P < 0.0005, η
2 = 0.37).
Blood pH was significantly higher with the SOL at 40
min (P = 0.009) post-ingestion than with the CAP and
significantly lower at 120min (P = 0.017) post-ingestion.
Blood pH peaked much later with the CAP (SOL =
71.67 ± 25.88 min, CAP = 125.83 ± 27.75 min, P = 0.001)
than with the SOL, although absolute changes were
comparable between conditions (P = 0.093).
Similarly, ingestion form had no significant effect on
base excess (BE) (F1.00, 11.00 = 0.69, P > 0.05, η
2 = 0.06) up
to 180 min post-ingestion. There was a significant effect
of time (F2.24, 24.68 = 118.08, P < 0.0005, η
2 = 0.92); BE in-
creased markedly for 60 min following ingestion of the
SOL, until a decrease occurred from the previous time
point at 180min (P = 0.034) post-ingestion (Fig. 4). In
contrast, BE rose progressively between 40 and 90 min
in the CAP condition, after which BE did not signifi-
cantly change (P > 0.05). A significant interaction was
found between condition and time (F2.20, 24.18 = 15.35,
P < 0.0005, η2 = 0.58). Blood BE was significantly
higher with the SOL at 20 (P = 0.014), 40 (P = 0.005)
and 60 (P = 0.034) min post-ingestion than with the
CAP and significantly lower at 130 (P = 0.022) and
140 (P = 0.019) min post-ingestion. Blood BE peaked
much later with CAP (SOL = 71.67 ± 18.01 min, CAP
= 112.50 ± 27.01 min, P < 0.0005) than with the SOL,
although absolute changes were comparable between
conditions (P = 0.071).
Discussion
This is the first study to investigate the effects of
gastro-resistant capsules on GI distress, bicarbonate
bioavailability and subsequent acid-base responses fol-
lowing NaHCO3 ingestion. The main finding was that
Table 2 Mean (± SD) pharmacokinetic response variables for bicarbonate in the SOL and CAP conditions, together with the
statistical significance of the difference
Outcome SOL CAP t test P value
Tlag (min) 20.0 ± 0.0* 31.7 ± 10.3* − 3.92 0.002
Tmax (min) 71.7 ± 18.0** 120.0 ± 28.9** − 5.35 < 0.0005
Cmax (mmol L
−1) 31.2 ± 1.1 31.8 ± 1.3 − 1.66 0.125
ΔCmax (mmol L
−1) 6.4 ± 1.3 6.5 ± 1.1 − 0.46 0.658
AUC0-3h (mmol min L
−1) 5277.9 ± 173.9 5286.0 ± 197.9 − 0.13 0.899
The asterisk denotes significant difference between SOL and CAP (*P < 0.05, **P < 0.0005). Tlag time to commence change in bicarbonate concentration, Tmax time
to peak concentration, Cmax peak bicarbonate concentration, ΔCmax absolute change in bicarbonate concentration, AUC0-3h area under the
concentration-time curve
Fig. 3 Individual changes in blood bicarbonate concentration
between conditions (SOL and CAP)
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delayed-release NaHCO3 mitigated GI distress, as
hypothesised. Fewer GI symptoms (~ 45.1%) were re-
ported with the delayed-release capsules, and the overall
severity was reduced (~ 47.1%) when compared to the
aqueous solution. Interestingly, reductions in GI symp-
toms were due to gastric but not intestinal symptoms, a
finding that has been suggested in the relevant literature
[15]. Gastrointestinal symptoms were negated with the
delayed-release capsules, with a reduction in the most
severe symptom experienced up to 3 h following supple-
mentation (Table 1). Given that GI symptoms may be
ergolytic [13, 14, 26], delayed-release NaHCO3 may be
more ergogenic in those who experience severe GI dis-
tress with the aqueous solution. Furthermore, since GI
distress may deter some individuals from using NaHCO3
as an ergogenic aid [7, 10], delayed-release NaHCO3
would appear to be a more favourable option for athletes
and coaches.
While necessary to achieve erogenicity [27], large bo-
luses (~ 200–300 mg kg−1 body mass) of NaHCO3 can
induce significant GI symptoms. In the current study,
there was a high incidence of GI distress with the aque-
ous solution, which is in agreement with some authors
[13] but not others [10, 28]. Symptoms are considered to
have both gastric and intestinal causes [8], a finding that
is supported by the current study. On entering the stom-
ach, NaHCO3 dissociates to sodium and bicarbonate
ions, the latter of which produces carbon dioxide during
the neutralisation of gastric acid [8]. Consequently, car-
bon dioxide tension increases exponentially with expos-
ure and is associated with gastric symptoms, such as
belching, nausea and stomach ache. Intestinal symp-
toms, though partly induced from elevated carbon diox-
ide tension in the intestinal lumen, originate from excess
sodium that aggravates the intestinal mucosa and creates
osmotic fluctuations leading to bowel urgency and diar-
rhoea [13]. Delayed-release capsules, partly formulated
with a polymeric barrier, have gastro-resistant properties
and can minimise disintegration in the stomach. Mitigat-
ing gastric symptoms may indeed have implications for
performance. Previous research indicates that symptoms
can inhibit high-intensity cycling performance [14],
while others have reported improvements irrespectively
[26]. Since numerous participants have withdrawn from
studies due to GI distress [29], previous research may
have underestimated the ergolytic effect of such
symptoms. Studies that have attempted to mitigate GI
symptoms following NaHCO3 ingestion have done so
using alternative dosing strategies. Gelatine capsules
co-ingested with a small high-carbohydrate (1.5 g kg−1
body mass) meal are currently regarded as the formula-
tion least likely to induce GI symptoms following
NaHCO3 ingestion [10]. In the current study, delayed-
release capsules were ingested after an overnight fast,
largely to minimise potential confounding effects of food
on acid-base changes. Nevertheless, co-ingestion with a
small high-carbohydrate meal may have further reduced
GI symptoms and warrants further investigation. Fur-
thermore, while comparison with an aqueous solution
was chosen based on its frequency of use within the lit-
erature, this may not be the case in the practice and is
thus a limitation to the study. Future work should look
to assess the pharmacokinetics of NaHCO3 administered
based on capsule composition only, so that the mechan-
ism underpinning bioavailability and reductions in GI
distress may be better understood.
In relation to bioavailability, both ingestion forms pro-
vided adequate sources of bicarbonate and displayed
similar pharmacokinetic properties. Increases in bicar-
bonate were comparable, with both forms exceeding the
6 mmol L−1 threshold suggested to enhance ergogenicity
[2]. Interestingly, some (N = 3) participants displayed en-
hanced bicarbonate availability (≥ 1 mmol L−1) with
delayed-release capsules (Fig. 4), while only one partici-
pant was found to have enhanced bicarbonate availability
of this magnitude with the aqueous solution. Similarly,
more participants achieved a 5 mmol L−1 (SOL N = 10,
CAP N = 11) and 6mmol L−1 (SOL: N = 8; CAP: N = 9)
Fig. 4 Mean (± SD) pH (a) and BE (b) responses. The asterisk denotes
significant difference between SOL and CAP conditions (P < 0.05)
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increase in bicarbonate with the delayed-release capsules
than with the aqueous solution. These results would be
explained by the gastric bypass model proposed by
Oliveira et al. [16], which includes the effect of gastric
transit time, and bicarbonate loss associated with neu-
tralisation. As suggested by these authors, reducing
bicarbonate neutralisation in the stomach increases bio-
availability when NaHCO3 is administered orally. Since
changes of ~ 1mmol L−1 in bicarbonate concentration
can positively affect performance [26], delayed-release
NaHCO3 may elicit superior ergogenicity. In contrast to
the aqueous solution, bicarbonate absorption did not
commence immediately following capsule ingestion, sug-
gesting that the delayed-release capsules were effective
[15, 30]. This result indicates that the capsules achieved
disintegration in the intestine, which had the effect of
lengthening (+ 48.3 min) the time to reach peak bicar-
bonate concentration. Bicarbonate peaked at ~ 120 min
post-ingestion with the delayed-release capsules, which
is later than previously reported with an aqueous solu-
tion in some studies [20] but not all [21]. Similar to pre-
vious studies [31–33], there was a high degree of
individual variability in the time to reach peak bicarbon-
ate concentration, although this was greater with the
capsules. The current findings for bicarbonate indicate
that for most individuals, delayed-release NaHCO3 may
increase the likelihood of inducing a performance-en-
hancing effect; however, as this was not consistent for all
individuals, decisions around ingestion form should be
based upon individual concentration-time profiles.
Metabolic alkalosis was induced earlier with the aque-
ous solution (~ 40 min) than with delayed-release cap-
sules (~ 60 min), although this state was maintained for
longer (+ 30min) when ingested in the delayed-release
form. Homeostatic regulation, through respiratory com-
pensation [34], may have been stimulated to a lesser ex-
tent with slower bicarbonate absorption, rather than the
abrupt elevation observed with an aqueous solution. Ex-
ercise performance timed with peak alkalosis may en-
hance the ergogenicity of NaHCO3 [7, 29]; therefore, it
is reasonable to consider that delayed-release may pro-
vide a larger ergogenic window. In a competitive setting,
this may be more favourable since performance may not
commence parallel with peak alkalosis due to variable
factors, such as sports fixtures. In the current study,
time to reach peak alkalosis was much later with
delayed-release NaHCO3 (~ 125 min) than with the
aqueous solution (~ 72min), with one participant peaking
at 180min post-ingestion. In a practical setting,
delayed-release NaHCO3 would have to be ingested
sooner than an aqueous solution to elicit similar acid-base
changes. This may be favourable in terms of ergogenicity
since GI symptoms were negligible at later time points. In
contrast, given that bicarbonate concentrations were
significantly lower with delayed-release NaHCO3 up to 60
min post-ingestion, this form may be less ergogenic when
ingested less than 60min prior to exercise.
Conclusions
In summary, delayed-release NaHCO3 mitigates GI
symptoms and these effects do not reflect the intestinal
component but rather the gastric component of overall
symptoms. The similar pharmacokinetic properties,
coupled with a delay in the time to reach metabolic al-
kalosis, mean that delayed-release NaHCO3 requires
earlier ingestion than with an aqueous solution to induce
comparable acid-base changes. The current study sup-
ports the gastric bypass model, which can be used as a
model for exploring various ingestion forms and modes
of administration generally. Lastly, delayed-release
NaHCO3 may be more ergogenic in those who experi-
ence severe gastrointestinal distress with an aqueous so-
lution, although this warrants further investigation.
Abbreviations
ΔCmax: Absolute change in bicarbonate concentration; AUC0-3h: Area under
the concentration-time curve; CAP: Delayed-release sodium bicarbonate;
Cmax: Peak bicarbonate concentration; CON: Control; NaHCO3: Sodium
bicarbonate; SOL: Aqueous solution sodium bicarbonate; Tlag: Time to
commence change in bicarbonate concentration; Tmax: Time to peak
bicarbonate concentration
Acknowledgements
We thank all those who gave their time to participate in the study, and for
the technical support of Scott Mosher and Ashleigh Warner. We thank
Capsugel® (France) who kindly provided us with the capsules (DRcaps™) free
of charge.
Funding
No funding was received for this study.
Availability of Data and Materials
Supporting data is available upon request (see corresponding author email).
Authors’ Contributions
The study was designed by NPH, LRM and AS. Data were collected by NPH,
NKL and LAG. The manuscript was written by NPH, with feedback provided
by LRM, AS and MMC. All authors approved the final version of the manuscript.
Ethics Approval and Consent to Participate
Ethical approval was granted by the University Research Ethics Committee
(URESC17-NH01), and each participant provided informed consent prior to
commencing the study (see methods section).
Consent for Publication
Each participant provided informed consent for the results of this study to
be published.
Competing Interests
The authors, Nathan Philip Hilton, Nicholas Keith Leach, S. Andy Sparks, Lewis
Anthony Gough, Melissa May Craig, Sanjoy Kumar Deb, and Lars Robert
McNaughton, declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Hilton et al. Sports Medicine - Open             (2019) 5:4 Page 7 of 8
Author details
1Sports Nutrition and Performance Group, Department of Sport and Physical
Activity, Edge Hill University, St Helens Road, Ormskirk L39 4QP, UK. 2School
of Health Sciences, Birmingham City University, Birmingham, UK. 3Therapies
Department, Liverpool Heart and Chest Hospital NHS Foundation Trust,
Liverpool, UK. 4School of Life Sciences, University of Westminster, London,
UK. 5Department of Sport and Movement Studies, Faculty of Health Science,
University of Johannesburg, Johannesburg, South Africa.
Received: 24 October 2018 Accepted: 14 January 2019
References
1. McNaughton LR, Gough L, Deb S, Bentley D, Sparks SA. Recent
developments in the use of sodium bicarbonate as an ergogenic aid. Curr
Sports Med Rep. 2016;15:233–44.
2. Carr AJ, Hopkins WG, Gore CJ. Effects of acute alkalosis and acidosis on
performance: a meta-analysis. Sports Med. 2011;41:801–14.
3. Christensen PM, Shirai Y, Ritz C, Nordsborg NB. Caffeine and bicarbonate for
speed. A meta-analysis of legal supplements potential for improving intense
endurance exercise performance. Front Physiol. 2017;8:240–56.
4. Matson LG, Tran ZV. Effects of sodium bicarbonate ingestion on anaerobic
performance: a meta-analytic review. Int J Sport Nutr. 1993;3:2–28.
5. Bellinger PM, Howe ST, Shing CM, Fell JW. Effect of combined β-alanine and
sodium bicarbonate supplementation on cycling performance. Med Sci
Sports Exerc. 2012;44:1545–51.
6. Higgins MF, James RS, Price MJ. The effects of sodium bicarbonate
(NaHCO3) ingestion on high intensity cycling capacity. J Sports Sci. 2013;31:
972–81.
7. Heibel AB, Perim PHL, Oliveira LF, McNaughton LR, Saunders B. Time to
optimize supplementation: modifying factors influencing the individual
responses to extracellular buffering agents. Front Nutr. 2018;5:1–12.
8. Turnberg LA, Fordtran JS, Carter NW, Rector FC. Mechanism of bicarbonate
absorption and its relationship to sodium transport in the human jejunum.
J Clin Invest. 1970;49:548–56.
9. Burke LM, Pyne DB. Bicarbonate loading to enhance training and
competitive performance. Int J Sports Physiol Perform. 2007;2:93–7.
10. Carr AJ, Slater GJ, Gore CJ, Dawson B, Burke LM. Effect of sodium
bicarbonate on [HCO3-], pH, and gastrointestinal symptoms. Int J Sport Nutr
Exerc Metab. 2011;21:189–94.
11. Miller P, Robinson AL, Sparks SA, Bridge CA, Bentley DJ, McNaughton LR.
The effects of novel ingestion of sodium bicarbonate on repeated sprint
ability. J Strength Cond Res. 2016;30:561–8.
12. Cameron SL, Mclay-Cooke RT, Brown RC, Gray AR, Fairbairn KA. Increased
blood pH but not performance with sodium bicarbonate supplementation
in elite rugby union players. Int J Sport Nutr. 2010;20:307–21.
13. Kahle LE, Kelly PV, Eloit KA, Weiss EP. Acute sodium bicarbonate loading has
negligible effects on resting and exercise blood pressure but causes
gastrointestinal distress. Nutr Res. 2013;33:479–86.
14. Saunders B, Sale C, Harris RC, Sunderland C. Sodium bicarbonate and high-
intensity-cycling capacity: variability in responses. Int J Sports Physiol
Perform. 2014;9:627–32.
15. Barbosa JAC, Conway BR, Merchant HA. Going natural: using polymers from
nature for gastroresistant applications. Br J Pharm. 2017;2:14–30.
16. Oliveira LF, Saunders B, Artioli GG. Is bypassing the stomach a means to
optimize sodium bicarbonate supplementation? A case study with a
postbariatric surgery individual. Int J Sport Nutr Exerc Metab. 2018;26:1–4.
17. DePauw K, Roelands B, Cheung SS, de Geus B, Rietjens G, Meeusen R.
Guidelines to classify subject groups in sport-science research. Int J Sports
Physiol Perform. 2013;8:111–22.
18. Bishop D, Edge J, Davis C, Goodman C. Induced metabolic alkalosis affects
muscle metabolism and repeated-sprint ability. Med Sci Sports Exerc. 2004;
36:807–13.
19. Reilly T. Human circadian rhythms and exercise. Crit Rev Biomed Eng. 1990;
18:165–80.
20. Gough LA, Deb SK, Sparks SA, McNaughton LR. The reproducibility of blood
acid base responses in male collegiate athletes following individualised
doses of sodium bicarbonate: a randomised controlled crossover study.
Sports Medi. 2017;47:2117–27.
21. Stannard RL, Stellingwerff T, Artioli GG, Saunders B, Cooper S, Sale C. Dose-
response of sodium bicarbonate ingestion highlights individuality in time
course of blood analyte responses. Int J Sports Nutr Exerc Metab. 2016;26:
445–53.
22. Grafen A, Hails R. Modern statistics for the life sciences. Oxford: Oxford
University Press; 2002.
23. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed.
Hillsdale: Erlbaum; 1988.
24. Atkinson G. Analysis of repeated measurements in physical therapy
research: multiple comparisons amongst level means and multi-factorial
designs. Phys Ther Sport. 2002;3:191–03.
25. Kinnear PR, Gray LTD. SPSS for windows made simple. London: Lawrence
Erlbaum; 1995.
26. McNaughton LR. Bicarbonate ingestion: effects of dosage on 60 s cycle
ergometry. J Sports Sci. 1992;10:415–23.
27. Jones RL, Stellingwerff T, Artioli GG, Saunders B, Cooper S, Sale C. Dose-
response of sodium bicarbonate ingestion highlights individuality in time
course of blood analyte responses. Int J Sport Nutr Exerc Metab. 2016;26:
445–53.
28. Montfoort MC, Van Dieren L, Hopkins WG, Shearman JP. Effects of ingestion
of bicarbonate, citrate, lactate, and chloride on sprint running. Med Sci
Sports Exerc. 2004;36:1239–43.
29. Gough LA, Deb SK, Sparks SA, McNaughton LR. The reproducibility of 4-km
time trial (TT) performance following individualised sodium bicarbonate
supplementation: a randomised controlled trial in trained cyclists. Sports
Med. 2017;3:34–44.
30. Marzorati M, Possemiers S, Verhelst A, Cadé A, Madit N, Van de Wiele T. A
novel hypromellose capsule, with acid resistance properties, permits the
targeted delivery of acid-sensitive products to the intestine. LWT Food Sci
Technol. 2015;60:544–51.
31. Renfree A. The time course of changes in plasma [H+] after sodium
bicarbonate ingestion. Int J Sports Physiol Perform. 2007;2:323–6.
32. Siegler JC, Marshall PW, Bray J, Towlson C. Sodium bicarbonate
supplementation and ingestion timing: does it matter? J Strength Cond Res.
2012;26:1953–8.
33. Siegler JC, Midgley AW, Polman RC, Lever R. Effects of various sodium
bicarbonate loading protocols on the time-dependent extracellular
buffering profile. J Strength Cond Res. 2010;24:2551–7.
34. Atherton JC. Acid-base balance: maintenance of plasma pH. Anaesth
Intensive Care Med. 2009;26:557–61.
Hilton et al. Sports Medicine - Open             (2019) 5:4 Page 8 of 8
